Is Carna Biosciences, Inc. (4572.T) a Buy, Sell, or Hold?
JPX : 4572.T
Carna Biosciences, Inc.
$314 JPY
-$18 (-5.42%)
- Volume
- 95.4K
- Average Volume
- 164.53K
- Market Capitalization
- $6.02B
- P/E Ratio
- -2.75
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $512.00
- Year Low
- $200.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.08
Industry, Sector & symbol
| Stock Exchange | JPX |
| CEO | Kohichiro Yoshino |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | 4572.T |
| CUSIP | None |
| CIK | None |
| Web | https://www.carnabio.com |
| Phone | 81 78 302 7039 |
| Currency | JPY |
| Employees | 61 |
| Country | JP |
Liquidity
| Debt-to-Equity Ratio | -13.45 |
| Payout Ratio | 0.00 |
| Current Ratio | 16.08 |
| Quick Ratio | 14.92 |
| Cash Ratio | 11.04 |
Sales & Book Value
| Annual Sales | $579.06M |
| Price / Sales | 9.73 |
| Cash Flow | 0.00 |
| Price / Cash Flow | 0.00 |
| Price / Book | -36.79 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$113.62 |
| Trailing P/E Ratio | -2.75 |
| PEG Ratio | -0.34 |
| P/E Growth | -0.34 |
| Net Income | -$2.17B |
| Net Margin | -352.90% |
| Pretax Margin | -352.44% |
| Return on Equity | -364.14% |
| Return on Assets | -98.73% |
Financials Score
| AltmanZ Score | -1.64 |
| Piotroski Score | 4.00 |
| Working Capital | 2.03B |
| Total Assets | 2.21B |
| Ebit | -2.05B |
| Market Cap | 6.37B |
| Total Liabilities | 2.38B |
Poll Results
About Carna Biosciences, Inc. (JPX:4572.T) Stock
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular a ... ssays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Frequently Asked Questions
-
What is the current Carna Biosciences, Inc. (4572.T) stock price?
-
Carna Biosciences, Inc.(JPX:4572.T) stock price is $314 in the last trading session. During the trading session, 4572.T stock reached the peak price of $512 while $200 was the lowest point it dropped to. The percentage change in 4572.T stock occurred in the recent session was --5.42% while the dollar amount for the price change in 4572.T stock was -$18.
-
4572.T's industry and sector of operation?
-
The JPX listed 4572.T is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of 4572.T?
-
Kunihisa Masuoka | Head of IP & Legal and Director
Akinori Arimura | GM of Clinical Development, R&D, Chief Development Officer of CarnaBio USA & Director
Kohichiro Yoshino | Chief Executive Officer, President & Representative Director
Masaaki Sawa | GM of Research & Development Division, Chief Scientific Officer and Director
Emi Yamamoto | GM of Business Mgt., Accounting, HR, General Affairs, Chief Financial Officer, Director & President - CarnaBio USA -
How many employees does 4572.T have?
-
Number of 4572.T employees currently stands at 61. 4572.T operates from BMA, 1-5-5 Minatojima-Minamimachi, Kobe, HY 650-0047, JP.
-
Link for 4572.T official website?
-
Official Website of 4572.T is: https://www.carnabio.com
-
How do I contact 4572.T?
-
4572.T could be contacted at phone #81 78 302 7039 and can also be accessed through its website. 4572.T operates from BMA, 1-5-5 Minatojima-Minamimachi, Kobe, HY 650-0047, JP.
-
How many shares of 4572.T are traded daily?
-
The average number of 4572.T shares traded daily for last 3 months was 164.53K.
-
What is the market cap of 4572.T currently?
-
The market value of 4572.T currently stands at $6.02B with its latest stock price at $314